1. Epidemiology and Global Health
  2. Microbiology and Infectious Disease
Download icon

Point of View: Tuberculosis innovations mean little if they cannot save lives

  1. Madhukar Pai  Is a corresponding author
  2. Jennifer Furin
  1. McGill University, Canada
  2. Manipal University, India
  3. Harvard Medical School, United States
Feature Article
Cite this article as: eLife 2017;6:e25956 doi: 10.7554/eLife.25956
2 figures

Figures

Figure 1
Download asset Open asset
Cumulative number of GeneXpert instrument modules and Xpert MTB/RIF cartridges procured under concessional pricing since 2010.

As of 31 December 2016, a total of 6,659 GeneXpert instruments (comprising 29,865 modules) and 23,140,350 Xpert MTB/RIF cartridges had been procured in the public sector in 130 of the 145 countries eligible for concessional pricing. Source: Cepheid & WHO (World Health Organization, 2017a).

https://doi.org/10.7554/eLife.25956.002
Figure 2
Download asset Open asset
Progress in bedaquiline (BDQ) and delamanid (DLM) global uptake by month compared with estimated need (goal).

Source: DR-TB STAT (DR-TB STAT, 2017).

https://doi.org/10.7554/eLife.25956.003

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)